Pharmaceutical Technology

APRIL 24, 2023

There, the data shows that patients on this regimen live longer lives along with having a greater period of time before disease progression, than with other treatments. CLL is regarded as the most common type of leukaemia in England where 3,157 patients were diagnosed with the disease in 2017, based on the institute’s announcement.

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

European Pharmaceutical Review

JUNE 12, 2023

This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” stated Henrik Wulff, executive vice president of Product Supply, Quality & IT at Novo Nordisk. The facility is expected to start producing API by early 2029.

Manufacturing 86

Manufacturing Government Pharmaceutical Medicine 86

Pharmaceutical Technology

JUNE 13, 2023

Construction has already commenced, with API production expected to begin by early 2029. The expansion project is anticipated to create 340 new jobs.

Manufacturing 52

Manufacturing Government Medicine Patients 52

pharmaphorum

OCTOBER 26, 2022

The first patient has already been enrolled into its FIBRONEER phase 3 programme for BI 1015550, which already has a breakthrough designation from the FDA after a positive phase 2 trial showed improved lung function in patients with IPF over a 12-week period. There are more than 200 lung disorders that can lead to pulmonary fibrosis.

Recruitment 97

Recruitment Prospecting Marketing Patients 97

European Pharmaceutical Review

JANUARY 2, 2024

AstraZeneca highlighted that beneficially, the Gracell FasTCAR platform significantly shortens manufacturing time, enhances T cell fitness and could improve the effectiveness of autologous CAR-T treatment in patients. According to the research, the global cell and gene therapy market is predicted to value $80 billion by 2029.

Manufacturing 80

Manufacturing Marketing Engineering Pharma 80

pharmaphorum

NOVEMBER 18, 2022

Dr John Lin, senior vice president of immune-oncology and head of bispecifics at Regeneron , said: “The collaboration will enable Regeneron and CytomX to combine our collective oncology expertise with two premier platforms […] to develop novel immunotherapies and research their potential to transform patient lives.”.

Biopharma 96

Biopharma Physicians Sales Patients 96

Pharmaceutical Technology

JANUARY 10, 2023

Many of the current existing therapies are often viewed by physicians as not optimal to addressing the needs of patients, and challenges remain such as improving patient compliance, safety profile, and addressing comorbidities of T2D. billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%.

Marketing 52

Marketing Physicians Leads Competition 52

Pharmaceutical Technology

MAY 23, 2023

In May 2021, Amgen’s Lumakras was approved for use in adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). billion in 2029. According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Lumakras, also known as sotorasib, has projected sales of $1.47

Pharma 52

Pharma Sales Pharmaceutical Patients 52

European Pharmaceutical Review

OCTOBER 26, 2023

Yet as the market continues to recognise the value of these treatments, especially with them having “clear benefits over current monotherapy and combination therapy options in cancer treatment”, it is unsurprising that GlobalData’s research predicted the ADC oncology therapy market will value more than $36 billion by 2029.

Patients 94

Patients Pharmaceutical Safety Marketing 94

pharmaphorum

NOVEMBER 24, 2022

The phase 3 ESCAPE-TRD study in 676 patients revealed that significantly more of those treated with Spravato were able to achieve remission from symptoms of depression without a relapse over 32 weeks of follow-up compared to quetiapine. and 14.1%, respectively.

Sales 52

Sales Patients Competition Marketing 52

Pharmaceutical Technology

FEBRUARY 3, 2023

Based on GlobalData’s patient-based forecast models, RA and CD are the top two indications contributing to this value, accounting for around 45% and 14%, respectively, of Humira’s sales. According to GlobalData’s Sales and Forecast Consensus database, Humira is anticipated to have garnered sales of $18.6 billion in 2022.

Marketing 52

Marketing Sales Patients Physicians 52

Pharmaceutical Technology

JULY 8, 2022

Blincyto has provided a strong positive signal to demonstrate the clinical and commercial viability of BiTEs, with 2021 company-reported global sales of $542 million and GlobalData’s analyst consensus forecast projecting peak annual sales of $771 million by 2029, thereby sparking further industry interest in this field. months vs. 4.0

Safety 59

Safety Sales Marketing Patients 59

Pharmaceutical Technology

APRIL 4, 2023

of NSCLC patients with exon 19 and 21 mutations develop resistance mutations at C797S. billion in 2029. More specifically, STX-241 targets exon 19 and exon 21 mutations alongside the co-occurring C797S mutation, whereas STX-721 focuses on exon 20 mutations. Up to 12.5% GlobalData is the parent company of Pharmaceutical Technology.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

pharmaphorum

DECEMBER 20, 2022

Wedbush Securities recently forecast more than $1 billion in 2029 sales for ensifentrine in the US alone, assuming a launch in the first quarter of 2024, and said today the stock could easily reach $30. Shares in Verona popped on the news, rising more than 40% to approach $19.50 and drive the company’s market cap to almost $1.5

Pharma 57

Pharma Sales Leads Marketing 57

Pharmaceutical Technology

JULY 15, 2022

Type 1 diabetes (T1D) is forecast to affect five million people in the eight major pharmaceutical markets, which are the US, France, Germany, Italy, Spain, UK, Japan, and Canada, by 2029. The spokeswoman goes on to say that these savings are not shared with the patients, who end up paying more for insulin than their insurance company.

Manufacturing 131

Manufacturing Insurance Pharmaceutical Marketing 131

European Pharmaceutical Review

NOVEMBER 16, 2023

billion by 2029. This requires modulating different components of the human immune system in a way that can address different patient segments, as the immune system is dysregulated in different ways across different tumour types. According to Data Bridge Market Research, the haematology /oncology market will value $14.83

Medicine 52

Medicine Manufacturing Medical Patients 52

PM360

APRIL 7, 2023

However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. Impact Beyond Medicare The IRA won’t just impact negotiation with the government either. Reference: 1.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

World of DTC Marketing

AUGUST 7, 2022

The passage of the Inflation Control bill is an excellent first step in limiting high drug costs, but our healthcare system is still built for profit at the expense of patients. Patients and doctors are tired, and insurance companies are raising rates after two years of making a surplus because nobody went to the doctor during the pandemic.

Insurance 263

Insurance Doctors Government Physicians 263

Pharmaceutical Technology

MAY 19, 2023

GlobalData forecasts Rituxan sales to plummet to just over $300m by 2029, while biosimilars will collectively surpass $1bn in sales in the same year, becoming responsible for nearly 80% of the total market share for rituximab products.

Sales 59

Sales Competition Marketing Patients 59

Pharmaceutical Technology

JUNE 13, 2023

The agent is being evaluated in relapsed/refractory (R/R) patients who have KMT2A-rearranged (KMT2ar) or NPM1-mutant (NPM1m) acute myeloid leukaemia (AML). Ziftomenib targets the menin-KMT2a protein-protein interaction that may occur in patients with KMT2ar or NPM1m genetic alterations. months for all patients achieving CRc.

Patients 52

Patients Sales Competition Safety 52

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker. Six cannabinoids have recently completed or are undergoing Phase II trials.

Medical 143

Medical Prescription Management Manufacturing 143

Pharmaceutical Technology

JUNE 22, 2008

This helps patients, businesses and doctors alike by settling expectations and creating a more efficient system for gathering, reporting and understanding such data.” The bill mostly relates to pharmaceutical companies, and the new amendments due to come in place in 2011 could impose further regulation.

Physicians 52

Physicians Doctors Pharmaceutical Consulting 52

Medico Reach

OCTOBER 17, 2022

billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The device replaces a connecting bone in the ankle joint and can be customized according to patient preference.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

European Pharmaceutical Review

JANUARY 18, 2024

The company predicted this will be “driven by an increase in the patient share of dual orexin receptor antagonists (DORAs)”. In the US in 2029 and in Japan in 2031, Belsomra is set to lose market exclusivity. percent from $3.2 billion in 2022 to $4.1 billion in 2032. percent between 2022 and 2032. million in sales by 2032.

Marketing 91

Marketing Sales Pharmacology Pharma 91

European Pharmaceutical Review

AUGUST 30, 2022

It was about solving cold-chain logistical challenges and ensuring the vaccine doses themselves could be administered easily and efficiently with minimal discomfort for patients. million by 2029, up from $122.287 million in 2021. We have been given a crash course in how to deliver vaccine doses successfully to billions of people.

Management 114

Management Manufacturing Marketing Side effects 114

European Pharmaceutical Review

JUNE 16, 2023

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.

Safety 102

Safety Electronics Recruitment Medical 102

pharmaphorum

AUGUST 31, 2022

In recent years, gene therapy has transitioned from a promising idea to a reality for patients, with many of the severe safety issues that emerged in early iterations of the technology being overcome. from 2021 to 2029. FDA backing. A broadening pipeline.

FDA 90

FDA Marketing Safety Patients 90

Medico Reach

OCTOBER 17, 2022

billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The device replaces a connecting bone in the ankle joint and can be customized according to patient preference.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52

Pharmaceutical Technology

JUNE 5, 2023

Any company that could provide DMTs would have ample opportunities for market entry, as they could bring about a major shift in patient treatment. The US market is driving this growth, forecasted to nearly triple from $2.4bn in 2023 to $7.4bn by 2029, as per GlobalData. GlobalData is the parent company of Pharmaceutical Technology.

Marketing 98

Marketing Pharmaceutical Patients 98

Pharmaceutical Technology

MAY 17, 2023

Orphan drug designations are granted to drugs that target rare disorders with fewer than 200,000 patients in the US. Primary biliary cholangitis is a rare autoimmune disease where small bile ducts are injured by the patient’s own immune system. billion in 2029. The condition gradually worsens and can result in liver failure.

Food and Drug Administration 52

Food and Drug Administration FDA Pharmaceutical Prospecting 52